Team

Dr. Daniel Koller

Head Investment Management
read more

Dr. Daniel Koller

Head Investment Management
« With an estimated growth of more than 10% a year, biotech is one of the most attractive sectors today »
  • Since 2004 with Bellevue Asset Management and since 2010 head investment management team of the BB Biotech AG  
  • 2001–2004 equity4life Asset Management Ltd, investment manager 
  • 2000–2001 UBS Warburg, equity analyst 
  • Master's degree in biochemistry of the Swiss Federal Institute of Technology (ETH) Zurich 
  • PhD in Biotechnology of the Swiss Federal Institute of Technology (ETH) Zurich and Cytos Biotechnology Ltd, Zurich 

The team of experienced biotech specialists has established an enviable track record in identifying and managing investment opportunities in the biotech sector.

Felicia Flanigan

Investment Management Team
read more

Felicia Flanigan

Investment Management Team
« Our investment strategy is focused on innovative drugs and therapies that offer sound value to healthcare systems »
  • Since 2004 with Bellevue Asset Management as Senior Portfolio Manager and head Bellevue Research Inc 
  • 1999–2004 Adams, Harkness & Hill, biotech equity analyst 
  • 1991–1999 SG Cowen, biotech equity analyst 
  • MBA, Suffolk University, Boston 
  • BA in communications, Boston College

Dallas Webb

Investment Management Team
read more

Dallas Webb

Investment Management Team
« Takeover activity in the sector will fuel significant valuation gains over a mid- and long-term horizon »
  • Since 2006 with Bellevue Asset Management as portfolio manager of the listed investment company BB Biotech AG  
  • 2004–2006 Stanford Group Company, senior vice president, equity analyst 
  • 2003–2004 Sterling Financial Investment Group, senior vice president, equity analyst 
  • 2002–2003 Adams, Harkness & Hill, associate, equity analyst 
  • MBA, Texas Christian University 
  • BS in microbiology and zoology, Louisiana State University 

Dr. Christian Koch

Investment Management Team
read more

Dr. Christian Koch

Investment Management Team
« Every second drug approved by regulators today originated from the lab of a biotech company »
  • Analyst and Portfolio Manager at the investment management team since 2014
  • 2013-2014 Sell-side Pharma & Biotech Equity Analyst at Bank am Bellevue in Küsnacht
  • 2010-2013 Research Associate at the Institute of Pharmaceutical Sciences, ETH Zurich
  • PhD in Chemoinformatics & Computational Drug Design, ETH Zurich
  • Master in Bioinformatics, Goethe University Frankfurt

Its academic expertise, many years of experience and collaboration, and a broad interest in all areas of medicine, biochemistry, and economics ensure an inspiring and constructive interdisciplinary dialogue within the team and with the Board of Directors as well as with external experts such as physicians and analysts.

Dr. Stephen Taubenfeld

Investment Management Team
read more

Dr. Stephen Taubenfeld

Investment Management Team
« Our investment portfolio is distinguished by a well-balanced risk/reward profile »
  • Since October 2013 with the investment management team as Portfolio Manager specializing in neurologic and psychiatric diseases
  • 2009-2013 Iguana Healthcare Partners, Senior Analyst and Founding Partner
  • 2008-2009 Merlin BioMed Group, Consultant
  • 2004-2008 Mount Sinai Hospital, New York, National Institutes of Health M.D./Ph.D. Fellow in Neuroscience
  • M.D. and Ph.D. in Neuroscience, Brown University School of Medicine

Dr. Maurizio Bernasconi

Investment Management Team
read more

Dr. Maurizio Bernasconi

Investment Management Team
« Biotech is driving innovation in medicine »
  • Since 2017 Investment Team BB Biotech
  • Previously since 2014 with Bank am Bellevue as financial analyst of the Pharma/Biotech sector
  • 2014: Chemist at SIGA Manufacturing, Ruswil, Zurich
  • 2009–2013: PhD in organic chemistry at the University of Basel
  • 2004–2009: master’s degree in chemistry, Swiss Federal Institute of Technology (ETH), Zurich

Jan Bootsma

Portfolio Management
read more

Jan Bootsma

Portfolio Management
« Sales and profits in the biotechnology industry have shown tremendous momentum »
  • Since 1995 Asset Management BAB N.V., Curaçao, managing director / portfolio management 
  • 1990–1995 CITCO, account manager securities administration 
  • 1985–1989 Multilift, head administration 
  • Higher economic education (HEAO) 

Hugo van Neutegem

Portfolio Management
read more

Hugo van Neutegem

Portfolio Management
« Sector newsflow remains positive and company pipelines are full »
  • Since 2001 BB Biotech subsidiary, Curaçao, chairman 
  • 2000–2001 CITCO, managing director 
  • 1992–2000 Ernst & Young, Netherlands and former the Netherlands Antilles 
  • Tax law, University of Leiden, the Netherlands

Nathalie Isidora-Kwidama

Portfolio Management
read more

Nathalie Isidora-Kwidama

Portfolio Management
« We want to thoroughly understand the activities of the companies we invest in »
  • Since 2007 Asset Management BAB N.V., Curaçao, portfolio management 
  • 2006–2007 NMT Services N.V., account manager / securities administrator 
  • 1997–2006 Decro Trust N.V., securities administration 
  • 1992–1996 CITCO, securities administration 
  • Modern business administration

Rudy Le Blanc

BoD / Managing director
read more

Rudy Le Blanc

BoD / Managing director
« A combination of scientific, medical and financial expertise is needed to achieve successful investment results in the biotech sector »
  • Board member and managing director of the BB Biotech branch office in Curaçao since 2013 
  • Various executive positions with the National Laboratory of Curaçao 
  • Operational director and still partner at a local Curaçao private medical laboratory 
  • Degree in medical science from the Emory University in Atlanta, USA

Dr. Silvia Schanz

Investor Relations
read more

Dr. Silvia Schanz

Investor Relations
  • Since 2012 with Bellevue Asset Management as Director Investor Relations for the investment company BB Biotech AG
  • 2011 – 2012 UBS Wealth Management, Buy-side Financial Analyst, Global Healthcare
  • 2008 – 2011 Vontobel Investment Banking, Sell-side Financial Analyst, Pharmaceuticals and Biotechnology
  • Certified International Investment Analyst (CIIA)
  • PhD / doctorate in Biochemistry of the Swiss Federal Institute of Technology (ETH) Zurich
  • Master in Biochemistry, minor in Business Administration of the University Freiburg

Claude Mikkelsen

Investor Relations
read more

Claude Mikkelsen

Investor Relations
  • Since 2012 with Bellevue Asset Management as Director Investor Relations for the investment company  BB Biotech AG
  • 2011-2012 Finance Director (interim), Nordic Region at Ecron Acunova A/S
  • 2009-2012 Senior Consultant, CMI Consulting
  • 2005-2009 Senior Vice President, Finance & Investor Relations at Pharmexa A/S
  • 2003-2005 Legal Consultant at Dako A/S
  • 2001-2003 Consultant at Deloitte
  • Master’s degree in Economy and Law, Aalborg University

    Maria-Grazia Iten-Alderuccio

    Investor Relations
    read more

    Maria-Grazia Iten-Alderuccio

    Investor Relations
    • Since 2007 with Bellevue Asset Management as Director Investor Relations BB Biotech AG
    • 2004–2007 Citco Fund Advisors, senior relationship manager
    • Master's degree in Linguistics from the University of Lausanne and Università degli Studi di Firenze, Italy